177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

#3537

Introduction: 177Lu-DOTATATE (PRRT) treatment is indicated in Spain in GEPNET but its activity in other somatostatin receptor-positive tumors is known.

Aim(s): The aim was to describe the differences in baseline characteristics and outcomes in patients treated with PRRT who had GEPNET vs those with tumors of other locations and histologies.

Materials and methods: Patients with somatostatin receptor–positive advanced tumors treated with PRRT were included in SEPTRALU multicenter registry between 2013 and 2021. Survival was evaluated using Kaplan-Meier method, response rate with RECIST and toxicity with CTCAEv3.0 criteria. The population was divided into 2 groups, patients with: 1) GEPNET and 2) other tumors.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Jimenez-Fonseca P, Pubul V, Belló P, Riesco-Martinez M, Aller J,

Keywords: PRRT, NET, Somatostatin receptor-positive tumor, Survival,